Watchdog rules that Merck violated the UK industry code of practice

doi:10.1136/bmj.332.7537.323-a

From trainee to consultant, BMJ Group offers doctors around the world tailored information, special events, learning resources and recruitment services at every step along their career path.

... by doctors, for doctors, for patients
We are open for entries!

Online learning

BMJ Learning

High-quality CME / CPD for doctors and other healthcare professionals. BMJ Learning features hundreds of accredited, peer-reviewed learning modules in text, video, and audio formats. Find out more

Courses and Qualifications

BMJ Masterclasses

BMJ Masterclasses, led by experts, help clinicians to use the latest evidence and recent guidelines in practice and meet their CPD/CME requirements. Find out more

Exam Preparation

The leading provider of online exam preparation, helping over 167,000 healthcare professionals to pass their exams. Find out more

onExamination

Search all BMJ research articles:

From

Limit by

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Owen Dyer

London

The UK pharmaceutical industry's regulatory watchdog has ruled that Merck violated the industry's code of practice by altering guidelines on hypertension treatment to give greater prominence to one of the company's own drugs.

The “ABCD” algorithm is intended to inform decisions on prescribing for high blood pressure in the guidelines of the British Hypertension Society, which were first published in the BMJ in March 2004 (BMJ 2004;328:634-40).

The letter A refers to angiotensin converting enzyme inhibitors and angiotensin receptor blockers, and the two types of drug are listed in the guidelines in that order. The guidelines specify that “all things being equal and when there are no compelling indications for …